<DOC>
	<DOC>NCT01692912</DOC>
	<brief_summary>Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score &lt;2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.</brief_summary>
	<brief_title>Psoriatic Arthritis Treat to Target vs. Usual Care</brief_title>
	<detailed_description>Canadian Rheumatologists will be randomized to treat their participants with active Psoriatic Arthritis to a target (disease activity score &lt;2.6), or as per their routine care. The aim of this study is to determine whether treating to a target results in greater disease improvement than treating patients using routine care.</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Psoriatic</mesh_term>
	<criteria>Psoriatic Arthritis as diagnosed by a rheumatologist and meeting ACR classification criteria for PsA or CASPAR criteria The subject must provide written informed consent for participation in the study before any study specific procedures are performed Subject has 3 or more SJC on 28 joint count Age &gt;=18 Subject has a history of being noncompliant Serious concomitant illnesses that in the investigator's opinion negate ability to optimally treat the patient If treating with TNF inhibitor, positive PPD &gt; 5mm who have not received INH for recommended course or untreated TB (ie CXR evidence of latent infection). Usual screening is in place for standard of care. Pregnancy, breastfeeding or considering pregnancy over the next 12 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Randomized</keyword>
	<keyword>Single blind</keyword>
	<keyword>Treat to target</keyword>
</DOC>